Search global stocks & ETFs...Ctrl K
Learn Mode
RX.V
Stock Profile
08-21 (Est)
Recommended Metric
Score Card
Explore Scores Tab
4.11
Good
Valuation Model
Key Score
5.00
Very Good
Management
5.00
Very Good
Growth
3.00
Average
Profitability
1.00
Very Bad
Fin. Health
3.00
Average
Dividends
3.00
Average
Analyst
1.00
Very Bad
Insider Transactions
Explore Insider Tab ›Buy Transactions
Sell Transactions
Buyback Transactions
Peers
Select stocks to compare
Price Targets & Ratings
View Analysis
1-year price targets, ending May 11, 2027
Current
CA$14.00
Baseline
High
CA$17.33
▲
23.75%
Avg
CA$16.83
▲
20.21%
Low
CA$16.67
▲
19.04%
Analyst Ratings based on 7 Analysts
Strong Buy
229%
Buy
457%
Hold
114%
Sell
000%
Strong Sell
000%
BioSyent, Inc. is a specialty pharmaceutical company, which engages in the development of pharmaceutical and healthcare products. The company is headquartered in Mississauga, Ontario. The Company, through its wholly owned subsidiaries, BioSyent Pharma Inc., and BioSyent Pharma International Inc., sources, acquires or in-licenses and further develops pharmaceutical and other healthcare products for sale in Canada and certain international markets. Hedley Technologies Ltd., and Hedley Technologies (USA) Inc., a wholly owned subsidiary, operates the Company’s business marketing biologically and health-friendly non-chemical insecticides. The Company’s products include Combogesic, Cathejell, FeraMAX Pd Therapeutic 150, FeraMAX Pd Maintenance 45, FeraMAX Pd Powder 15, Gelclair, Inofolic, Proktis-M, RepaGyn and Tibella, among others. Combogesic is for the short-term management of mild to moderate acute pain and the reduction of fever in adults. FeraMAX Pd Therapeutic 150 is for the treatment of iron deficiency anemia. The firm also provides specialized healthcare products for dental hygiene and oral health.Read More
Stock News
View All Updates
BioSyent Inc. 2026 Q1 - Results - Earnings Call Presentation
2wSeekingAlpha
BioSyent to Present at 2026 Bloom Burton & Co. Healthcare Investor Conference
7wYahoo
FeraMAX is Canada's Top-Ranked Iron Supplement for 11 Consecutive Years
9wYahoo
BioSyent Announces Grant of Restricted Share Units
10wYahoo
BioSyent Inc. 2025 Q4 - Results - Earnings Call Presentation
10wSeekingAlpha
BioSyent Inc. (RX:CA) Q4 2025 Earnings Call Prepared Remarks Transcript
10wSeekingAlpha
BioSyent Releases Financial Results for Fourth Quarter and Full Year 2025
11wYahoo
BioSyent Schedules Fourth Quarter and Full Year 2025 Earnings Release for March 19, 2026
12wYahoo
BioSyent Announces Closing of the Acquisition of Oral Science Inc.
13wYahoo
BioSyent (CVE:RX) Has Announced That It Will Be Increasing Its Dividend To CA$0.055
16wYahoo
BioSyent to Acquire Oral Science Inc.
16wYahoo
BioSyent Declares First Quarter 2026 Dividend
18wYahoo
Individual investors account for 57% of BioSyent Inc.'s (CVE:RX) ownership, while institutions account for 19%
22wYahoo
BioSyent Announces Renewal of Normal Course Issuer Bid
24wYahoo
Investors in BioSyent (CVE:RX) have seen notable returns of 83% over the past three years
25wYahoo